nach oben

Current Rheumatology Reports

Erschienen in:

01.05.2020 | Systemic Lupus Erythematosus (G Tsokos, Section Editor)

An Update on the Pathogenesis of Skin Damage in Lupus

verfasst von: Qianwen Li, Haijing Wu, Suqing Zhou, Ming Zhao, Qianjin Lu

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Lupus erythematosus (LE) is characterized by broad and varied clinical forms ranging from a localized skin lesion to a life-threatening form with severe systemic manifestations. The overlapping between cutaneous LE (CLE) and systemic LE (SLE) brings difficulties to physicians for early accurate diagnosis and sometimes may lead to delayed treatment for patients. We comprehensively review recent progress about the similarities and differences of the main three subsets of LE in pathogenesis and immunological mechanisms, with a particular focus on the skin damage.

Recent Findings

Recent studies on the mechanisms contributing to the skin damage in lupus have shown a close association of abnormal circulating inflammatory cells and abundant production of IgG autoantibodies with the skin damage of SLE, whereas few evidences if serum autoantibodies and circulating inflammatory cells are involved in the pathogenesis of CLE, especially for the discoid LE (DLE). Till now, the pathogenesis and molecular/cellular mechanism for the progress from CLE to SLE are far from clear. But more and more factors correlated with the differences among the subsets of LE and progression from CLE to SLE have been found, such as the mutation of IRF5, IFN regulatory factors and abnormalities of plasmacytoid dendritic cells (PDCs), Th1 cells, and B cells, which could be the potential biomarkers for the interventions in the development of LE.

Summary

A further understanding in pathogenesis and immunological mechanisms for skin damage in different subsets of LE makes us think more about the differences and cross-links in the pathogenic mechanism of CLE and SLE, which will shed a light in predictive biomarkers and therapies in LE.

Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8(6):467–73.PubMedCrossRef

Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol. 1981;4(4):471–5.PubMedCrossRef

Frances C, et al. Classification of dermatologic manifestations in lupus erythematosus. Ann Med Interne (Paris). 2003;154(1):33–44.

Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2007;5(12):1124–37.PubMedCrossRef

Werth VP. Cutaneous lupus: insights into pathogenesis and disease classification. Bull NYU Hosp Jt Dis. 2007;65(3):200–4.PubMed

Wieczorek IT, et al. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol. 2014;150(3):291–6.PubMedCrossRef

Ortona E, et al. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita. 2016;52(2):205–12.PubMed

Skonieczna K, Woźniacka A, Czajkowski R, Styczyński J, Krenska A, Robak E, et al. X-linked TLR7 gene polymorphisms are associated with diverse immunological conditions but not with discoid lupus erythematosus in Polish patients. Postepy Dermatol Alergol. 2018;35(1):26–32.PubMedPubMedCentralCrossRef

• Skonieczna K, et al. Genetic similarities and differences between discoid and systemic lupus erythematosus patients within the Polish population. Postepy Dermatol Alergol. 2017;34(3):228–32. In this study, researchers have compared the frequencies of SNPs located inSTAT4,ITGAM, andTNXBgenes among DLE, SLE, and healthy controls, suggesting certain differences in the molecular background between DLE and SLE.PubMedPubMedCentralCrossRef

10.

Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, Herrero C. Cutaneous lupus erythematosus: clinical and immunological study of 308 patients stratified by gender. Clin Exp Dermatol. 2010;35(7):729–35.PubMedCrossRef

11.

Petersen MP, Möller S, Bygum A, Voss A, Bliddal M. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus. 2018;27(9):1424–30.PubMedCrossRef

12.

Tedeschi SK, Bermas B, Costenbader KH. Sexual disparities in the incidence and course of SLE and RA. Clin Immunol. 2013;149(2):211–8.PubMedCrossRef

13.

Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56(4):1251–62.CrossRefPubMed

14.

Doria A, Cutolo M, Ghirardello A, Zampieri S, Vescovi F, Sulli A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum. 2002;47(2):202–9.PubMedCrossRef

15.

Colasanti T, et al. Autoantibodies to estrogen receptor alpha interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2012;64(3):778–87.PubMedCrossRef

16.

Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–38.PubMedCrossRef

17.

Trancart M, Cavailhes A, Balme B, Skowron F. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2008;158(3):628–9.PubMedCrossRef

18.

Yell JA, Burge SM. The effect of hormonal changes on cutaneous disease in lupus erythematosus. Br J Dermatol. 1993;129(1):18–22.PubMedCrossRef

19.

Scofield RH, Bruner GR, Namjou B, Kimberly RP, Ramsey-Goldman R, Petri M, et al. Klinefelter’s syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58(8):2511–7.PubMedPubMedCentralCrossRef

20.

Cooney CM, Bruner GR, Aberle T, Namjou-Khales B, Myers LK, Feo L, et al. 46,X,del(X)(q13) Turner’s syndrome women with systemic lupus erythematosus in a pedigree multiplex for SLE. Genes Immun. 2009;10(5):478–81.PubMedPubMedCentralCrossRef

21.

Lee YH, Choi SJ, Ji JD, Song GG. Association between toll-like receptor polymorphisms and systemic lupus erythematosus: a meta-analysis update. Lupus. 2016;25(6):593–601.PubMedCrossRef

22.

Laffont S, et al. X-chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-alpha production of plasmacytoid dendritic cells from women. J Immunol. 2014;193(11):5444–52.PubMedCrossRef

23.

Zeng J, et al. Novel biomarkers for systemic lupus erythematosus. Biomark Med. 2017;11(8):677–86.PubMedCrossRef

24.

Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol. 1978;98(5):497–506.PubMedCrossRef

25.

Millard LG, Rowell NR, Rajah SM. Histocompatibility antigens in discoid and systemic lupus erythematosus. Br J Dermatol. 1977;96(2):139–44.PubMedCrossRef

26.

Morris DL, et al. MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun. 2014;15(4):210–7.PubMedPubMedCentralCrossRef

27.

Osmola A, Namysł J, Jagodziński PP, Prokop J. Genetic background of cutaneous forms of lupus erythematosus: update on current evidence. J Appl Genet. 2004;45(1):77–86.PubMed

28.

Jarvinen TM, et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol. 2010;19(2):123–31.PubMedCrossRef

29.

Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012;71(3):463–8.PubMedCrossRef

30.

Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015;17:182.PubMedPubMedCentralCrossRef

31.

Werth VP, et al. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol. 2000;115(4):726–30.PubMedCrossRef

32.

Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4(5):253–63.PubMedCrossRef

33.

Jeffries MA, Sawalha AH. Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumatol. 2011;6(4):423–39.CrossRef

34.

Hewagama A, Gorelik G, Patel D, Liyanarachchi P, McCune W, Somers E, et al. Overexpression of X-linked genes in T cells from women with lupus. J Autoimmun. 2013;41:60–71.PubMedPubMedCentralCrossRef

35.

Zhao M, et al. DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J Autoimmun. 2014;54:127–36.PubMedCrossRef

36.

Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun. 2013;43:78–84.PubMedPubMedCentralCrossRef

37.

Zhao M, et al. Increased 5-hydroxymethylcytosine in CD4(+) T cells in systemic lupus erythematosus. J Autoimmun. 2016;69:64–73.PubMedCrossRef

38.

Zhao M, et al. IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Ann Rheum Dis. 2016;75(11):1998–2006.PubMedCrossRef

39.

Renauer P, Coit P, Jeffries MA, Merrill JT, McCune W, Maksimowicz-McKinnon K, et al. DNA methylation patterns in naive CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus. Lupus Sci Med. 2015;2(1):e000101.PubMedPubMedCentralCrossRef

40.

Zhou Y, Qiu X, Luo Y, Yuan J, Li Y, Zhong Q, et al. Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells. Lupus. 2011;20(13):1365–71.PubMedCrossRef

41.

Zhang Z, Song L, Maurer K, Petri MA, Sullivan KE. Global H4 acetylation analysis by ChIP-chip in systemic lupus erythematosus monocytes. Genes Immun. 2010;11(2):124–33.PubMedCrossRef

42.

Zhao M, Tan Y, Peng Q, Huang C, Guo Y, Liang G, et al. IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation. Nat Commun. 2018;9(1):583.PubMedPubMedCentralCrossRef

43.

Zhao H, Wang L, Luo H, Li QZ, Zuo X. TNFAIP3 downregulation mediated by histone modification contributes to T-cell dysfunction in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(5):835–43.CrossRef

44.

Ghorai A, Ghosh U. miRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-transcriptional processing of coding genes. Front Genet. 2014;5:100.PubMedPubMedCentralCrossRef

45.

Khan D, Dai R, Ansar Ahmed S. Sex differences and estrogen regulation of miRNAs in lupus, a prototypical autoimmune disease. Cell Immunol. 2015;294(2):70–9.PubMedCrossRef

46.

•• Sole C, et al. MicroRNA expression profiling identifies miR-31 and miR-485-3p as regulators in the pathogenesis of discoid cutaneous lupus. J Invest Dermatol. 2019;139(1):51–61. This report has shown a specific microRNA expression profile in DLE-affected skin as compared with SCLE.PubMedCrossRef

47.

Zhang H, Liao X, Sparks JB, Luo XM. Dynamics of gut microbiota in autoimmune lupus. Appl Environ Microbiol. 2014;80(24):7551–60.PubMedPubMedCentralCrossRef

48.

Huang C, et al. Disordered cutaneous microbiota in systemic lupus erythematosus. J Autoimmun. 2019:102391.PubMedCrossRef

49.

Reichrath J, et al. Biologic effects of light: an enlighting prospective. Anticancer Res. 2016;36(3):1339–43.PubMed

50.

McGrath H Jr. Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus. Lupus. 2017;26(12):1239–51.PubMedPubMedCentralCrossRef

51.

Kuhn A, Sonntag M, Richter-Hintz D, Oslislo C, Megahed M, Ruzicka T, et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol. 2001;45(1):86–95.PubMedCrossRef

52.

Kuhn A, Wozniacka A, Szepietowski JC, Gläser R, Lehmann P, Haust M, et al. Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. J Invest Dermatol. 2011;131(8):1622–30.PubMedCrossRef

53.

Tsukazaki N, et al. Photoprovocation test and immunohistochemical analysis of inducible nitric oxide synthase expression in patients with Sjogren’s syndrome associated with photosensitivity. Br J Dermatol. 2002;147(6):1102–8.PubMedCrossRef

54.

Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus. 2010;19(9):1036–46.PubMedCrossRef

55.

Kim A, Chong BF. Photosensitivity in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2013;29(1):4–11.PubMedPubMedCentralCrossRef

56.

Kuhn A, Fehsel K, Lehmann P, Krutmann J, Ruzicka T, Kolb-Bachofen V. Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus. J Invest Dermatol. 1998;111(1):149–53.PubMedCrossRef

57.

Wang PW, et al. Comparison of the biological impact of UVA and UVB upon the skin with functional proteomics and immunohistochemistry. Antioxidants (Basel). 2019:8(12).PubMedCentralCrossRef

58.

Norris DA, Whang K, David-Bajar K, Bennion SD. The influence of ultraviolet light on immunological cytotoxicity in the skin. Photochem Photobiol. 1997;65(4):636–46.PubMedCrossRef

59.

Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol. 2001;144(5):958–66.PubMedCrossRef

60.

Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science. 1999;285(5429):898–900.PubMedCrossRef

61.

Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183(6):2645–56.PubMedCrossRef

62.

Yagita H, et al. CD95 ligand in graft rejection. Nature. 1996;379(6567):682.PubMedCrossRef

63.

Blokland SLM, et al. Increased expression of Fas on group 2 and 3 innate lymphoid cells is associated with an interferon signature in systemic lupus erythematosus and Sjogren’s syndrome. Rheumatology (Oxford). 2019;58(10):1740–5.CrossRef

64.

Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum. 2006;54(3):939–50.PubMedCrossRef

65.

Suzuki N, Sakane T. Abnormal Fas and Fas ligand expression of lymphocytes in patients with SLE. Nihon Rinsho. 1996;54(7):1955–9.PubMed

66.

Liphaus BL, Kiss MHB, Carrasco S, Palmeira P, Goldenstein-Schainberg C, Carneiro-Sampaio M. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus. Clin Rheumatol. 2017;36(12):2847–52.PubMedCrossRef

67.

Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179(4):1317–30.PubMedCrossRef

68.

Oke V, Vassilaki I, Espinosa A, Strandberg L, Kuchroo VK, Nyberg F, et al. High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. J Invest Dermatol. 2009;129(8):2000–10.PubMedCrossRef

69.

Zahn S, Rehkämper C, Ferring-Schmitt S, Bieber T, Tüting T, Wenzel J. Interferon-alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol. 2011;165(5):1118–23.PubMedCrossRef

70.

Yin Q, et al. Ultraviolet B irradiation induces skin accumulation of plasmacytoid dendritic cells: a possible role for chemerin. Autoimmunity. 2014;47(3):185–92.PubMedCrossRef

71.

Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46(1):191–201.PubMedCrossRef

72.

Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994;152(7):3685–92.PubMed

73.

Safi R, al-Hage J, Abbas O, Kibbi AG, Nassar D. Investigating the presence of neutrophil extracellular traps in cutaneous lesions of different subtypes of lupus erythematosus. Exp Dermatol. 2019;28(11):1348–52.PubMedCrossRef

74.

Guiducci C, Tripodo C, Gong M, Sangaletti S, Colombo MP, Coffman RL, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med. 2010;207(13):2931–42.PubMedPubMedCentralCrossRef

75.

Villanueva E, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187(1):538–52.PubMedCrossRef

76.

Wang H, et al. Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheumatol. 2015;67(12):3190–200.PubMedCrossRef

77.

Vermi W, Lonardi S, Morassi M, Rossini C, Tardanico R, Venturini M, et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology. 2009;214(9–10):877–86.PubMedCrossRef

78.

Blomberg S, et al. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus. 2001;10(7):484–90.PubMedCrossRef

79.

Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, et al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol. 2008;45(1):259–65.PubMedCrossRef

80.

Wenzel J, et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol. 2005;205(4):435–42.PubMedCrossRef

81.

Mendez-Flores S, et al. Cytokines and effector/regulatory cells characterization in the physiopathology of cutaneous lupus erythematous: a cross-sectional study. Mediat Inflamm. 2016;2016:7074829.CrossRef

82.

Mendez-Flores S, et al. Inflammatory chemokine profiles and their correlations with effector CD4 T cell and regulatory cell subpopulations in cutaneous lupus erythematosus. Cytokine. 2019;119:95–112.PubMedCrossRef

83.

Farkas L, Beiske K, Lund-Johansen F. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001;159:237–43.PubMedPubMedCentralCrossRef

84.

Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8(6):492–502.PubMedPubMedCentralCrossRef

85.

Reefman E, Kuiper H, Limburg PC, Kallenberg CG, Bijl M. Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients. Ann Rheum Dis. 2008;67(1):11–8.PubMedCrossRef

86.

Muhammad Yusoff F, Wong KK, Mohd Redzwan N. Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity. 2019:1–13.

87.

Magro CM, et al. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol. 2010;37(6):659–71.PubMedCrossRef

88.

Yang J, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472–83.PubMedCrossRef

89.

Tanasescu C, Balanescu E, Balanescu P, Olteanu R, Badea C, Grancea C, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010;21(3):202–7.PubMedCrossRef

90.

Jabbari A, et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol. 2014;134(1):87–95.PubMedCrossRef

91.

Franz B, Fritzsching B, Riehl A, Oberle N, Klemke CD, Sykora J, et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum. 2007;56(6):1910–20.PubMedCrossRef

92.

Gilliam JN, Hurd ER. Comparison of circulating T and B lymphocytes in discoid versus systemic lupus erythematosus. Clin Immunol Immunopathol. 1976;6(2):149–55.PubMedCrossRef

93.

Vital EM, Wittmann M, Edward S, Yusof MYM, MacIver H, Pease CT, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(6):1586–91.PubMedCrossRef

94.

Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship. Br J Dermatol. 2004;150(4):693–700.PubMedCrossRef

95.

Grassi M, Capello F, Bertolino L, Seia Z, Pippione M. Identification of granzyme B-expressing CD-8-positive T cells in lymphocytic inflammatory infiltrate in cutaneous lupus erythematosus and in dermatomyositis. Clin Exp Dermatol. 2009;34(8):910–4.PubMedCrossRef

96.

Robak E. Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. Mediat Inflamm. 2001;10(4):179–89.CrossRef

97.

Merola JF, Prystowsky SD, Iversen C, Gomez-Puerta JA, Norton T, Tsao P, et al. Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. J Am Acad Dermatol. 2013;69(1):19–24.PubMedPubMedCentralCrossRef

98.

Chong BF, Tseng LC, Lee T, Vasquez R, Li QZ, Zhang S, et al. IgG and IgM autoantibody differences in discoid and systemic lupus patients. J Invest Dermatol. 2012;132(12):2770–9.PubMedPubMedCentralCrossRef

99.

Luo YJ, Tan GZ, Yu M, Li KW, Liu YY, Guo Q, et al. Correlation of cutaneous immunoreactants in lesional skin with the serological disorders and disease activity of systemic lupus erythematosus. PLoS One. 2013;8(8):e70983.PubMedPubMedCentralCrossRef

100.

Deocharan B, Qing X, Beger E, Putterman C. Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies. Lupus. 2002;11(12):865–71.PubMedCrossRef

101.

Zieve GW, Khusial PR. The anti-Sm immune response in autoimmunity and cell biology. Autoimmun Rev. 2003;2(5):235–40.PubMedCrossRef

102.

Riemekasten G, Hahn BH. Key autoantigens in SLE. Rheumatology (Oxford). 2005;44(8):975–82.CrossRef

103.

Koutouzov S, et al. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin N Am. 2004;30(3):529–58 ix.CrossRef

104.

Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest. 1994;94(1):184–92.PubMedPubMedCentralCrossRef

105.

Jovelin F, Mostoslavsky G, Amoura Z, Chabre H, Gilbert D, Eilat D, et al. Early anti-nucleosome autoantibodies from a single MRL+/+ mouse: fine specificity, V gene structure and pathogenicity. Eur J Immunol. 1998;28(11):3411–22.PubMedCrossRef

106.

Arbuckle MR, McClain M, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33.PubMedCrossRef

107.

Merola JF, et al. Is chronic cutaneous discoid lupus protective against severe renal disease in patients with systemic lupus erythematosus? J Drugs Dermatol. 2011;10(12):1413–20.PubMed

108.

Li QZ, Zhou J, Wandstrat AE, Carr-Johnson F, Branch V, Karp DR, et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2007;147(1):60–70.PubMedPubMedCentral

109.

Li QZ, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest. 2005;115(12):3428–39.PubMedCrossRef

110.

Liu L, et al. The features of skin inflammation induced by lupus serum. Clin Immunol. 2016;165:4–11.PubMedCrossRef

111.

Li J, et al. Chinese SLE treatment and research group registry: III. association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus. J Immunol Res. 2014;2014:809389.PubMedPubMedCentral

112.

Deng GM, et al. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. J Immunol. 2010;184(12):7154–61.PubMedCrossRef

113.

Zhang J, Jiang J, Guo L. Different prognoses of two types of subacute cutaneous lupus erythematosus: a follow-up of 40 cases. Chin J Dermatol. 2001.

114.

Haber JS, Merola JF, Werth VP. Classifying discoid lupus erythematosus: background, gaps, and difficulties. Int J Womens Dermatol. 2017;3(1 Suppl):S62–6.PubMedPubMedCentralCrossRef

115.

Dey-Rao R, Smith JR, Chow S, Sinha AA. Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease. Genomics. 2014;104(2):144–55.PubMedCrossRef

116.

Ehrenstein MR, McSweeney E, Swane M, Worman CP, Goldstone AH, Isenberg DA. Appearance of anti-DNA antibodies in patients treated with interferon-alpha. Arthritis Rheum. 1993;36(2):279–80.PubMedCrossRef

117.

Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med. 1990;227(3):207–10.PubMedCrossRef

118.

Meller S. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment. Arthritis & Rheumatism. 2005;52:1504–16.CrossRef

119.

Meller S, Winterberg F, Gilliet M, Müller A, Lauceviciute I, Rieker J, et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005;52(5):1504–16.PubMedCrossRef

120.

Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4(3):e1000017.PubMedPubMedCentralCrossRef

121.

Sheshachalam A, et al. Granule protein processing and regulated secretion in neutrophils. Front Immunol. 2014;5:448.PubMedPubMedCentralCrossRef

122.

Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol. 2012;30:459–89.PubMedCrossRef

123.

Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–75.PubMedCrossRef

124.

Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.PubMedCrossRef

125.

Denny MF, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184(6):3284–97.PubMedCrossRef

126.

Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–9.PubMedCrossRef

127.

Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983–94.PubMedPubMedCentralCrossRef

128.

Mauri C, Menon M. The many faces of type I interferon in systemic lupus erythematosus. J Clin Invest. 2015;125(7):2562–4.PubMedPubMedCentralCrossRef

129.

Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, et al. Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest. 2001;108(9):1331–9.PubMedPubMedCentralCrossRef

130.

Heine G, et al. A shift in the Th(1)/Th(2) ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease. Nephrol Dial Transplant. 2002;17(10):1790–4.PubMedCrossRef

131.

Mok MY, Wu HJ, Lo Y, Lau CS. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol. 2010;37(10):2046–52.PubMedCrossRef

132.

Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127(3):385–93.PubMedCrossRef

133.

Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J, et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(2):R53.PubMedPubMedCentralCrossRef

134.

Alunno A, et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol. 2012;2012:823085.PubMedPubMedCentralCrossRef

135.

Biswas PS, Aggarwal R, Levesque MC, Maers K, Ramani K. Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients. Int J Rheum Dis. 2015;18(6):646–53.PubMedCrossRef

136.

Ali N, Rosenblum MD. Regulatory T cells in skin. Immunology. 2017;152(3):372–81.PubMedPubMedCentralCrossRef

137.

Wenzel J, Uerlich M, Wörrenkämper E, Freutel S, Bieber T, Tüting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br J Dermatol. 2005;153(5):1011–5.PubMedCrossRef

138.

Kind P, Lipsky PE, Sontheimer RD. Circulating T- and B-cell abnormalities in cutaneous lupus erythematosus. J Invest Dermatol. 1986;86(3):235–9.PubMedCrossRef

139.

Mori M, Pimpinelli N, Romagnoli P, Bernacchi E, Fabbri P, Giannotti B. Dendritic cells in cutaneous lupus erythematosus: a clue to the pathogenesis of lesions. Histopathology. 1994;24(4):311–21.PubMedCrossRef

140.

Ortaldo JR, Mason AT, O'Shea JJ. Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med. 1995;181(1):339–44.PubMedCrossRef

141.

Yin S, et al. Hyperactivation and in situ recruitment of inflammatory Vδ2 T cells contributes to disease pathogenesis in systemic lupus erythematosus. Sci Rep. 2015;5(1).

142.

Paul S, Singh AK, Shilpi, Lal G. Phenotypic and functional plasticity of gamma-delta (gammadelta) T cells in inflammation and tolerance. Int Rev Immunol. 2014;33(6):537–58.PubMedCrossRef

143.

Li X, et al. Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the presence of TGF-beta and their involvement in the pathogenesis of systemic lupus erythematosus. J Immunol. 2011;186(12):6693–700.PubMedCrossRef

144.

Lu Z, et al. Elevated apoptosis and impaired proliferation contribute to downregulated peripheralγδT cells in patients with systemic lupus erythematosus. Clin Dev Immunol. 2013;2013:1–9.

145.

Volc-Platzer B, Anegg B, Milota S, Pickl W, Fischer G. Accumulation of gamma delta T cells in chronic cutaneous lupus erythematosus. J Invest Dermatol. 1993;100(1):84S–91S.PubMedCrossRef

146.

•• Quelhas da Costa R, et al. Assessment of response to B-Cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154(12):1432–40. This is one of the largest long-term follow-up (>6 months) studies comparing and assessing the response of SLE patients with or without CLE lesions to rituximab treatment. There is a significant absence of response to rituximab treatment in the SLE patients with DLE lesions, indicating potentially different pathogenesis in DLE subtype.PubMedPubMedCentralCrossRef

147.

O'Brien JC, Hosler GA, Chong BF. Changes in T cell and B cell composition in discoid lupus erythematosus skin at different stages. J Dermatol Sci. 2017;85(3):247–9.PubMedCrossRef

148.

Chong BF, et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. J Dermatol Sci. 2014;73(3):216–24.PubMedCrossRef

149.

Reich A, Marcinow K, Bialynicki-Birula R. The lupus band test in systemic lupus erythematosus patients. Ther Clin Risk Manag. 2011;7:27–32.PubMedPubMedCentralCrossRef

150.

Zecevic RD, Pavlovic MD, Stefanovic D. Lupus band test and disease activity in systemic lupus erythematosus: does it still matter? Clin Exp Dermatol. 2006;31(3):358–60.PubMedCrossRef

151.

Beutner EH, Blaszczyk M, Jablonska S, Chorzelski TP, Kumar V, Wolska H. Studies on criteria of the European Academy of Dermatology and Venerology for the classification of cutaneous lupus erythematosus. I. Selection of clinical groups and study factors. Int J Dermatol. 1991;30(6):411–7.PubMedCrossRef

152.

Fabre VC, et al. Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol. 1991;127(7):1006–11.PubMedCrossRef

153.

Kulthanan K, et al. Chronic discoid lupus erythematosus in Thailand: direct immunofluorescence study. Int J Dermatol. 1996;35(10):711–4.PubMedCrossRef

154.

Jordon RE. Cutaneous immunofluorescence. Clin Rheum Dis. 1982;8(2):479–91.PubMed

155.

Yu M, Li KW, Tan GZ, Luo T, Xu DQ, Wang L. The gender disparity of immunoreactants in lesional skin of lupus erythematosus patients. Clin Exp Rheumatol. 2012;30(1):103–5.PubMed

156.

Gronhagen CM, et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335–41.PubMedCrossRef

157.

Ohata C, et al. Comparative study of direct immunofluorescence in discoid lupus erythematosus and bullous pemphigoid. Am J Dermatopathol. 2016;38(2):121–3.PubMedCrossRef

158.

Baek YS, et al. Cutaneous lupus erythematosus and its association with systemic lupus erythematosus: a nationwide population-based cohort study in Korea. J Dermatol. 2019.

159.

Arkin LM, Ansell L, Rademaker A, Curran ML, Miller ML, Wagner A, et al. The natural history of pediatric-onset discoid lupus erythematosus. J Am Acad Dermatol. 2015;72(4):628–33.PubMedCrossRef

160.

Das NK, Dutta RN, Sengupta SR. Skin lesions in lupus erythematosus: a marker of systemic involvement. Indian J Dermatol. 2011;56(5):537–40.PubMedPubMedCentralCrossRef

161.

Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012;166(1):29–35.PubMedCrossRef

Titel: An Update on the Pathogenesis of Skin Damage in Lupus
verfasst von: Qianwen Li
Haijing Wu
Suqing Zhou
Ming Zhao
Qianjin Lu
Publikationsdatum: 01.05.2020
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 5/2020
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-020-00893-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen